Zevra Therapeutics Appoints CFO Justin Renz with 25+ Years Biopharma Finance Experience
Zevra Therapeutics appointed Justin Renz as Chief Financial Officer effective March 9, 2026, leveraging his more than 25 years of biopharma financial leadership across capital markets and commercial-stage operations. His experience leading strategic transactions and product launches at Ardelyx and Correvio will underpin Zevra’s rare disease expansion and commercialization strategy.
1. CFO Appointment Details
Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. This leadership change strengthens Zevra’s executive team as it advances its commercial-stage business in rare diseases.
2. Renz’s Biopharma Finance Background
Justin Renz brings over 25 years of financial leadership experience, including roles as Chief Financial & Operations Officer at Ardelyx and President and CFO at Correvio Pharma. He also served as CFO at Karyopharm Pharmaceuticals and Zalicus, overseeing strategic transactions and commercial launches.
3. Strategic Implications for Zevra
Renz’s background in capital markets and product commercialization is expected to support Zevra’s efforts to expand geographic access for its Niemann-Pick disease type C therapy. His expertise will aid in executing strategic transactions and enhancing shareholder value as Zevra broadens its rare disease pipeline.